story of the week
Trastuzumab Emtansine Improves Overall Survival in Previously Treated HER2+ Metastatic Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Trastuzumab Emtansine Versus Treatment of Physician's Choice in Patients With Previously Treated HER2-Positive Metastatic Breast Cancer (TH3RESA): Final Overall Survival Results From a Randomised Open-Label Phase 3 Trial
Lancet Oncol 2017 May 16;[EPub Ahead of Print], IE Krop, SB Kim, AG Martin, PM LoRusso, JM Ferrero, T Badovinac-Crnjevic, S Hoersch, M Smitt, H WildiersFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.